In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Respironics, Inc.

http://www.respironics.com

Latest From Respironics, Inc.

Finance Watch: Clinical-Stage Autoimmune Start-Ups Garner Big Investments

Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds. 

Financing Immune Disorders

Philips Agrees Terms Of US Consent Decree, Remains Bullish On 2024

Royal Philips CEO Roy Jakobs updated investors on progress of the company’s operating plan 2023-25, US actions and litigation on the Respironics portfolio, patient safety, quality and the order book as it announced Q4 2023 revenues.

Business Strategies Commercial

News We're Watching: FDA Announces Meetings On Ortho Safety And Radiology; News Orgs Sue FDA For Philips Docs, ITC Delays Apple Watch Case; And More

This week, FDA announced plans for cybersecurity and meetings to discuss orthopedic device safety and radiological devices. ProPublica and the Pittsburgh Post-Gazette insist that the FDA to divulge more information about the ongoing Philips recalls. SetPoint is trying to treat Crohn's disease with its vagus nerve stimulator. ITC delayed the Apple Watch patent case again.

FDA Clinical Trials

Philips Healthcare Doubles Down On Creating An Agile Future

After an admittedly difficult 2022 for a variety of reasons, Philips Healthcare is ready to tackle 2023 and beyond by reducing business complexities, slimming staff numbers further and crucially implementing a new value creation strategy under recently appointed CEO Roy Jakobs.

Diagnostic Imaging Business Strategies
See All

Company Information

  • Other Names / Subsidiaries
    • Philips
UsernamePublicRestriction

Register